Luspatercept as Potential Treatment for Congenital Sideroblastic Anemia
Ruben Van Dijck, Alice M Goncalves Silva, Anita W. Rijneveld
Abstract
intradermal route allows for dose sparing of the prophylactic MVA-BN vaccine against mpox; 80% of the vaccine dose was spared, as compared with the subcutaneous route.We believe that the adverse events that were observed in this trial would be acceptable to persons seeking protection against mpox.
Topics & Concepts
MedicineSideroblastic anemiaAnemiaPediatricsHematinicInternal medicineHemoglobinopathies and Related DisordersErythrocyte Function and PathophysiologyParvovirus B19 Infection Studies